365 related articles for article (PubMed ID: 34026622)
1. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
Sun W; Zhang Q; Wang R; Li Y; Sun Y; Yang L
Front Oncol; 2021; 11():648687. PubMed ID: 34026622
[TBL] [Abstract][Full Text] [Related]
2. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
3. Targeting ATR in cancer medicine.
Sundar R; Brown J; Ingles Russo A; Yap TA
Curr Probl Cancer; 2017; 41(4):302-315. PubMed ID: 28662958
[TBL] [Abstract][Full Text] [Related]
4. Targeting DNA Damage Response in Prostate and Breast Cancer.
Wengner AM; Scholz A; Haendler B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
[TBL] [Abstract][Full Text] [Related]
5. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
6. Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer.
Deng S; Vlatkovic T; Li M; Zhan T; Veldwijk MR; Herskind C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230796
[TBL] [Abstract][Full Text] [Related]
7. Genetic vulnerabilities upon inhibition of DNA damage response.
Wang C; Tang M; Chen Z; Nie L; Li S; Xiong Y; Szymonowicz KA; Park JM; Zhang H; Feng X; Huang M; Su D; Hart T; Chen J
Nucleic Acids Res; 2021 Aug; 49(14):8214-8231. PubMed ID: 34320214
[TBL] [Abstract][Full Text] [Related]
8. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy.
Silva SB; Wanderley CWS; Colli LM
Front Immunol; 2022; 13():826577. PubMed ID: 35211121
[TBL] [Abstract][Full Text] [Related]
10. ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.
Southgate HED; Chen L; Tweddle DA; Curtin NJ
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32354033
[No Abstract] [Full Text] [Related]
11. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Wengner AM; Siemeister G; Lücking U; Lefranc J; Wortmann L; Lienau P; Bader B; Bömer U; Moosmayer D; Eberspächer U; Golfier S; Schatz CA; Baumgart SJ; Haendler B; Lejeune P; Schlicker A; von Nussbaum F; Brands M; Ziegelbauer K; Mumberg D
Mol Cancer Ther; 2020 Jan; 19(1):26-38. PubMed ID: 31582533
[TBL] [Abstract][Full Text] [Related]
12. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
[TBL] [Abstract][Full Text] [Related]
13. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
[No Abstract] [Full Text] [Related]
14. Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape.
Qiu Y; Hu X; Zeng X; Wang H
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(11):1569-1576. PubMed ID: 36305726
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ATR-CHK1 Axis in Cancer Therapy.
Rundle S; Bradbury A; Drew Y; Curtin NJ
Cancers (Basel); 2017 Apr; 9(5):. PubMed ID: 28448462
[TBL] [Abstract][Full Text] [Related]
16. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
Gachechiladze M; Skarda J; Bouchalova K; Soltermann A; Joerger M
Front Oncol; 2020; 10():581217. PubMed ID: 33224881
[TBL] [Abstract][Full Text] [Related]
17. Targeting the DNA Damage Response Machinery for Lung Cancer Treatment.
Venugopala KN
Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558926
[TBL] [Abstract][Full Text] [Related]
18. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Hunia J; Gawalski K; Szredzka A; Suskiewicz MJ; Nowis D
Front Mol Biosci; 2022; 9():1073797. PubMed ID: 36533080
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Effect of a Mesothelin-Targeted
Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
[TBL] [Abstract][Full Text] [Related]
20. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
